secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061505
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports Q3 product revenue $102.7M, net income $20.9M, PHOENIX topline Q2 2024
--------------------------------------------------------------------------------

- Net product revenue $102.7M (Q3) vs $98.2M (Q2 2023) and $0.3M (Q3 2022).
- Net income $20.9M ($0.30 diluted EPS) compared to net loss $53.8M in Q3 2022.
- Cash, equivalents and short-term investments $355.0M at Sept 30, 2023.
- Post hoc analysis: median overall survival 10.4 months longer with AMX0035 vs historical control.
- CHMP reaffirmed negative EU opinion; final decision end 2023. PHOENIX Phase 3 topline expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/0000950170-23-061505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/amlx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer